Aspire-Lakewood Holdings vs Pfizer
Aspire-Lakewood Holdings (ASBP) and Pfizer (PFE) side by side: how big they are, what they earn, how their shares have moved and what insiders, members of Congress and funds reported. Figures from filings and closing prices; none of this is a view on either stock.
- Market value
- $10M
- Last close
- $7.13
- 12 months
- −93.9%
- Market value
- $156B
- Last close
- $27.40
- 12 months
- +12.3%
At a glance
- Aspire-Lakewood Holdings earns 99% of its revenue in the United States, Pfizer 59%.
- By market value, Pfizer ($156.2B) is about 15617 times Aspire-Lakewood Holdings ($10M).
- Over the last 12 months Aspire-Lakewood Holdings's share price moved −93.9% and Pfizer's +12.3%; against the S&P 500 that is −99.6 points and +6.6 points.
- In their last fiscal years Aspire-Lakewood Holdings kept -394725.1% of revenue as net income and Pfizer 12.4%.
- In the last 90 days insiders reported 0 open-market purchases at Aspire-Lakewood Holdings and 0 at Pfizer; members of Congress disclosed 0 trades in Aspire-Lakewood Holdings and 0 in Pfizer.
- Next results: Aspire-Lakewood Holdings not announced, Pfizer Feb 1, 2027.
How each one makes money: Aspire-Lakewood Holdings revenue · Pfizer revenue
Share prices on one chart
Aspire-Lakewood Holdings and Pfizer, and up to three more you add, drawn on the same scale so you can see which moved more.
Face to face
The figures that separate the two, drawn to the same scale. Every figure is also in the table below.
Size
Market value
Revenue, last fiscal year
Net income, last fiscal year
Every figure
| Aspire-Lakewood Holdings ASBPNASDAQ · Pharmaceutical Preparations | Pfizer PFENYSE · Pharmaceuticals | |
|---|---|---|
| Size and profitability | ||
| Market value | $10M | $156B |
| Revenue, last fiscal year | $6.2K | $62.6B |
| Net income, last fiscal year | −$24.5M | $7.77B |
| Net marginNet income as a share of revenue | -394725.1% | 12.4% |
| Free cash flow | −$4.92M | |
Prices are end-of-day closes, and fundamentals are the companies' last annual figures from their SEC filings: a − or + in the table is a fact of the filing or the close, not a forecast. Market value is the company-level figure at the last close. Counts are of records OQRO holds, by their date; insider history since 2006 comes from the SEC's insider transactions data sets and every filing since. Planned sales under a 10b5-1 plan are counted like other sales.
Compare with another company
Pfizer against
Common questions
How is Aspire-Lakewood Holdings different from Pfizer?
Aspire-Lakewood Holdings (ASBP) is in Pharmaceutical Preparations on NASDAQ, with $6.2K of revenue in its last fiscal year and a net margin of -394725.1%. Pfizer (PFE) is in Pharmaceuticals on NYSE, with $62.6B of revenue in its last fiscal year and a net margin of 12.4%. Aspire-Lakewood Holdings earns 99% of its revenue in the United States, Pfizer 59%. The table above sets their figures side by side; it compares filings and is not a view on either stock.
How do Aspire-Lakewood Holdings and Pfizer compare in size?
Pfizer has the larger market value: Aspire-Lakewood Holdings $10M and Pfizer $156B, at the last close.
Whose share price rose more over the last 12 months, ASBP or PFE?
Over the last 12 months Aspire-Lakewood Holdings moved −93.9% and Pfizer +12.3%. Past price moves say nothing about the future.
Which has had more insider buying, Aspire-Lakewood Holdings or Pfizer?
Since 2006, Pfizer insiders reported 25 open-market purchases against 4 for Aspire-Lakewood Holdings. These are counts of what was filed, not a view on either stock.
Do members of Congress trade ASBP or PFE?
In the last 12 months, members of Congress disclosed 0 trades in Aspire-Lakewood Holdings (ASBP) and 11 in Pfizer (PFE).
When did insiders last buy ASBP and PFE?
See the record behind any of these
A free account opens the full history of every insider and company since 2006, the screener, alerts, Congress trades and fund moves.
Aspire-Lakewood Holdings pagePfizer pageRare insider trades this weekAll comparisons
https://oqro.io/compare/asbp-vs-pfe







